After joining the study, you will begin a 6-month treatment with rezafungin acetate (REZZAYO). This medication is designed to treat chronic pulmonary aspergillosis (CPA), which is a fungal infection in the lungs caused by Aspergillus that has been present for 3 months or longer.

The medication will be administered as a solution for infusion. This means you will receive it through an intravenous (IV) line. The dosage is 200 mg of rezafungin acetate in the form of a powder that will be made into a concentrated solution.

At the beginning of the study, you will complete several assessments to establish your starting condition. These include:

– Completing the St George’s Respiratory Questionnaire, which asks about your breathing problems and how they affect your life

– Having your weight measured

– Undergoing a CT scan of your chest (a detailed X-ray that shows images of your lungs)

– Having blood tests to measure Aspergillus IgG levels (antibodies that your body produces in response to the fungal infection)

– Completing quality of life questionnaires including the EQ-5D-5L and Respiratory Symptom score

After 3 months of treatment, you will return for a follow-up assessment that includes:

– Repeating the St George’s Respiratory Questionnaire

– Having your weight measured again to check for any changes

– Blood tests to measure Aspergillus IgG levels

– Completing the EQ-5D-5L and Respiratory Symptom questionnaires

– Physical examination and laboratory tests to monitor your overall health and check for any side effects

– Assessment of any changes in antibiotic or steroid prescriptions you may need

– Checking respiratory samples to see if Aspergillus is still present

At the end of the 6-month treatment period, you will complete a final assessment that includes all the same tests as the 3-month assessment plus:

– A final CT scan of your chest to assess any changes in your lungs

– Complete evaluation of your response to treatment based on improvements in symptoms, weight changes, and lung imaging

– Final review of any hospitalizations that may have occurred during the study

– Final safety assessment including review of any side effects experienced during the study

Throughout the entire 6-month study period, your safety will be monitored through:

– Tracking of any adverse events (side effects or unexpected health issues)

– Monitoring for any serious adverse events that might require medical attention

– Regular check-ins regarding your health status

– Testing to see if the Aspergillus fungus has developed resistance to the medication

– Recording any hospitalizations related to your lung condition